-
21
-
22
-
23
Erratum to “Overexpression of PGC-1 Increases Fatty Acid Oxidative Capacity of Human Skeletal Muscle Cells”
Published 2013-01-01Get full text
Article -
24
Development of Spray-Dried Micelles, Liposomes, and Solid Lipid Nanoparticles for Enhanced Stability
Published 2025-01-01Get full text
Article -
25
Roles for Prlhr/GPR10 and Npffr2/GPR74 in feeding responses to PrRP
Published 2025-02-01Get full text
Article -
26
Cell clone selection—impact of operation modes and medium exchange strategies on clone ranking
Published 2025-01-01Get full text
Article -
27
AB ÜYE DEVLETLERİNDE COVID-19 AŞILARININ ÖN SATIN ALMA SÖZLEŞMELERİ İÇİN VİYANA SATIM ANTLAŞMASININ (CISG’İN) UYGULANABİLİRLİĞİ
Published 2022-08-01“…Avrupa Komisyonu, Avrupa Birliği’nde COVID-19 aşısının üretimi, satın alınması ve temini için çeşitli aşı üretici firmaları ile ön satın alma sözleşmesi imzalamıştır. AstraZeneca, Curevac Ag ve Pfizer Inc./BioNTech ile yapılan sözleşme metinlerinin bazı kısımları karartılarak yayımlanmıştır. …”
Get full text
Article -
28
Prevention of respiratory syncytial virus infection in children. Recommendations of the Polish Society of Paediatrics and the National Paediatric Consultant
Published 2024-12-01“…The monoclonal antibody nirsevimab (AstraZeneca and Sanofi Pasteur) is used in newborns and infants to protect against severe RSV infection. …”
Get full text
Article -
29
Update from Canadian Respirology Program Directors
Published 2004-01-01“…Submitted by Elizabeth Tullis MD FRCPC Associate Professor of Medicine, Respirology Program Director, University of Toronto, Toronto, Ontario The Canadian Organization of Pulmonary Program Directors (COPPD) had their first meeting in Montreal on November 7, 2003, which was sponsored by an unrestricted educational grant from AstraZeneca Canada Inc. This meeting was held in conjunction with the Royal College of Physicians and Surgeons (RCPS) Respirology Subspecialty Committee meeting held on November 6, 2003, and with the first Canadian Division Directors meeting held on November 8, 2003.…”
Get full text
Article -
30
-
31
-
32
Asthma Control in Canada Remains Suboptimal: The Reality of Asthma Control (TRAC) Study
Published 2006-01-01Get full text
Article -
33
-
34
-
35
IL-33 Mediates Lung Inflammation by the IL-6-Type Cytokine Oncostatin M
Published 2020-01-01Get full text
Article -
36
A Descriptive-Multivariate Analysis of Community Knowledge, Confidence, and Trust in COVID-19 Clinical Trials among Healthcare Workers in Uganda
Published 2023“…We also found a high level of skepticism and possible community resistance to DNA recombinant vaccines, such as the Oxford–AstraZeneca vaccine. Preference for herbal treatments (38/260; 14.6%, 95% CI: 10.7–19.3) currently being promoted by the Ugandan government raises major policy concerns. …”
Get full text
Article -
37
COVID-19 Booster Vaccines Administration in Different Countries
Published 2021-12-01“…This includes COVID-19 vaccines by Pfizer-BioNTech, Moderna, AstraZeneca, Janssen, Sinovac, and Sinopharm. Findings suggested that protection against COVID-19 provided by these vaccines may be waning or that the protection reduces against variants of concern (VOC) or even inadequate protection of the primary vaccination for some risk groups. …”
Get full text
Article -
38
Metyrapone for Long-Term Medical Management of Cushing’s Syndrome
Published 2013-01-01Get full text
Article -
39
Neurological manifestations associated with COVID-19 vaccine
Published 2025-01-01“…Most of the published cases occurred in temporal association with the Pfizer vaccine (BNT162b2), followed by the AstraZeneca vaccine (ChAdOX1-S). Conclusions: It is not possible to establish a causal relationship between these adverse events and COVID-19 vaccines with the currently existing data, nor to calculate the frequency of appearance of these disorders. …”
Get full text
Article -
40